J&J's Janssen Says FDA Gave Niraparib Breakthrough Therapy Designation
October 03 2019 - 5:43PM
Dow Jones News
By Stephen Nakrosis
The Janssen Pharmaceutical Cos. of Johnson & Johnson (JNJ)
said Thursday the U.S. Food and Drug Administration had granted
breakthrough therapy designation for Niraparib, a treatment for
certain prostate cancer patients.
The company said the designation was based on data from its
Galahad study, which is evaluating Niraparib as a treatment for
certain patients with metastatic castration-resistant prostate
cancer.
The company is also studying Niraparib in combination for the
treatment of metastatic prostate cancer.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 03, 2019 17:28 ET (21:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
